These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7958482)

  • 1. Bacteriophages as tools for vaccine development.
    Hatfull GF; Barsom L; Chang L; Donnelly-Wu M; Lee MH; Levin M; Nesbit C; Sarkis GJ
    Dev Biol Stand; 1994; 82():43-7. PubMed ID: 7958482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression systems for study of mycobacterial gene regulation and development of recombinant BCG vaccines.
    DasGupta SK; Jain S; Kaushal D; Tyagi AK
    Biochem Biophys Res Commun; 1998 May; 246(3):797-804. PubMed ID: 9618292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Mycobacterium bovis BCG.
    Bastos RG; Borsuk S; Seixas FK; Dellagostin OA
    Vaccine; 2009 Nov; 27(47):6495-503. PubMed ID: 19720367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Auxotrophic complementation as a selectable marker for stable expression of foreign antigens in Mycobacterium bovis BCG.
    Borsuk S; Mendum TA; Fagundes MQ; Michelon M; Cunha CW; McFadden J; Dellagostin OA
    Tuberculosis (Edinb); 2007 Nov; 87(6):474-80. PubMed ID: 17888740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guérin.
    Lee MH; Pascopella L; Jacobs WR; Hatfull GF
    Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3111-5. PubMed ID: 1901654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of genetic systems for the mycobacteria.
    Jacobs WR; Snapper SB; Lugosi L; Jekkel A; Melton RE; Kieser T; Bloom BR
    Acta Leprol; 1989; 7 Suppl 1():203-7. PubMed ID: 2503991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable expression of Leptospira interrogans antigens in auxotrophic Mycobacterium bovis BCG.
    Seixas FK; Borsuk S; Fagundes MQ; Hartwig DD; Da Silva EF; Cerqueira GM; Dellagostin OA
    Biol Res; 2010; 43(1):13-8. PubMed ID: 21157628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the development of bacterial vector technology.
    Kochi SK; Killeen KP; Ryan US
    Expert Rev Vaccines; 2003 Feb; 2(1):31-43. PubMed ID: 12901595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Instability and site-specific excision of integration-proficient mycobacteriophage L5 plasmids: development of stably maintained integrative vectors.
    Springer B; Sander P; Sedlacek L; Ellrott K; Böttger EC
    Int J Med Microbiol; 2001 Mar; 290(8):669-75. PubMed ID: 11310445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycobacterium avium subsp. paratuberculosis-specific mpt operon expressed in M. bovis BCG as vaccine candidate.
    Heinzmann J; Wilkens M; Dohmann K; Gerlach GF
    Vet Microbiol; 2008 Aug; 130(3-4):330-7. PubMed ID: 18343053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of live recombinant BCG vaccines.
    Hanson MS; Bansal GP; Langermann S; Stover CK; Orme I
    Dev Biol Stand; 1995; 84():229-36. PubMed ID: 7796958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the mycobacteriophage L5 attachment site, attP.
    Peña CE; Lee MH; Pedulla ML; Hatfull GF
    J Mol Biol; 1997 Feb; 266(1):76-92. PubMed ID: 9054972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope-tagging vectors for the expression and detection of recombinant proteins in mycobacteria.
    Spratt JM; Ryan AA; Britton WJ; Triccas JA
    Plasmid; 2005 May; 53(3):269-73. PubMed ID: 15848231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant BCG as a candidate oral vaccine vector.
    Barletta RG; Snapper B; Cirillo JD; Connell ND; Kim DD; Jacobs WR; Bloom BR
    Res Microbiol; 1990; 141(7-8):931-9. PubMed ID: 2101484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacteriophage L5 infection of Mycobacterium bovis BCG: implications for phage genetics in the slow-growing mycobacteria.
    Fullner KJ; Hatfull GF
    Mol Microbiol; 1997 Nov; 26(4):755-66. PubMed ID: 9427405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of cell-mediated immune response in mice by whole HIV-1 gag in Mycobacterium bovis BCG as a live vaccine candidate.
    Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Sutthent R; Sawanpanyalert P; Warachit P
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):113-22. PubMed ID: 19323043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardized viability test required for preventive, immunomodulator and recombinant BCG vaccine.
    Lugosi L
    Dev Biol Stand; 1992; 77():211-5. PubMed ID: 1426664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live bacterial delivery systems for development of mucosal vaccines.
    Thole JE; van Dalen PJ; Havenith CE; Pouwels PH; Seegers JF; Tielen FD; van der Zee MD; Zegers ND; Shaw M
    Curr Opin Mol Ther; 2000 Feb; 2(1):94-9. PubMed ID: 11249657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superinfection immunity of mycobacteriophage L5: applications for genetic transformation of mycobacteria.
    Donnelly-Wu MK; Jacobs WR; Hatfull GF
    Mol Microbiol; 1993 Feb; 7(3):407-17. PubMed ID: 8459767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.